LOVELAND, Colo., July 20 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA) ("Heska" or the "Company") today reported financial results for its second quarter ended June 30, 2010.
(Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)
"Results exceeded our revenue and income guidance," said Robert Grieve, Heska's Chairman and CEO. "As we have previously discussed, this quarter represented a difficult comparison as we are no longer selling our previous handheld blood analysis instrument and affiliated consumables. Core Companion Animal Health Revenue excluding these handheld instruments and consumables increased in 2010 as compared to the prior year period. We have been disappointed by the weak economic environment in the United States which we believe is having an impact on our instrument sales. Despite these challenges, we paid the remaining balance on our long term debt prior to the end of our second quarter, a milestone we have been anticipating for some time."
Investor Conference Call
Management will conduct a conference call on Tuesday, July 20, 2010 at 9:00 a.m. MDT (11:00 a.m. EDT) to discuss the second quarter 2010 financial results. To participate, dial (877) 941-6009 (domestic) or (480) 629-9770 (international); the conference call access number is 4329553. The conference call will also be broadcast live over the Internet at http://www.heska.com. To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software. Telephone replays of the conference call will be available for playback until August 3, 2010. The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international). The webcast replay may be accessed from Heska's home page at www.heska.com until August 3, 2010.
About Heska
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
Forward-Looking Statements
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the performance of third parties to whom Heska has granted substantial marketing rights including, but not limited to, Schering-Plough Animal Health Corporation; risks related to obtaining regulatory approval to authorize shipment of Heska's cattle vaccines; risks related to Heska's ability to maintain its listing on the NASDAQ Capital Market; uncertainties related to Heska's ability to market and sell its products successfully and economically; uncertainties related to Heska's ability to generate profits and cash flow in future periods; uncertainties related to the future success of Heska's efforts to prevent the production of non-compliant products in its OVP segment; risks related to Heska's reliance on third-party suppliers, which is significant; competition; uncertainties related to Heska's ability to maintain all regulatory compliance required to continue to manufacture and sell vaccines and pharmaceuticals; uncertainties related to the impact of transfer restrictions on Heska's stock, which were approved by Heska stockholders at Heska's Annual Meeting of Stockholders on May 4, 2010; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.
Financial Table Follows:
Consolidated Statements of Operations |
|||||||||||||||||
Three Months Ended |
Six Months Ended |
||||||||||||||||
2009 |
2010 |
2009 |
2010 |
||||||||||||||
Revenue, net: |
|||||||||||||||||
Core companion animal health |
$ |
16,879 |
13,731 |
$ |
35,016 |
$ |
29,523 |
||||||||||
Other vaccines, pharmaceuticals and products |
1,750 |
1,376 |
3,754 |
3,278 |
|||||||||||||
Total revenue, net |
18,629 |
15,107 |
38,770 |
32,801 |
|||||||||||||
Cost of revenue |
11,598 |
9,260 |
24,366 |
20,749 |
|||||||||||||
Gross profit |
7,031 |
5,847 |
14,404 |
12,052 |
|||||||||||||
Operating expenses: |
|||||||||||||||||
Selling and marketing |
3,622 |
3,656 |
7,380 |
7,692 |
|||||||||||||
Research and development |
405 |
388 |
851 |
845 |
|||||||||||||
General and administrative |
1,994 |
2,010 |
4,146 |
4,210 |
|||||||||||||
Total operating expenses |
6,021 |
6,054 |
12,377 |
12,747 |
|||||||||||||
Operating income (loss) |
1,010 |
(207) |
2,027 |
(695) |
|||||||||||||
Interest and other expense, net |
41 |
122 |
206 |
295 |
|||||||||||||
Income (loss) before income taxes |
969 |
(329) |
1,821 |
(990) |
|||||||||||||
Income tax expense (benefit) |
390 |
(164) |
782 |
(495) |
|||||||||||||
Net income (loss) |
$ |
579 |
$ |
(165) |
$ |
1,039 |
$ |
(495) |
|||||||||
Basic net income (loss) per share |
$ |
0.01 |
$ |
0.00 |
$ |
0.02 |
$ |
(0.01) |
|||||||||
Diluted net income (loss) per share |
$ |
0.01 |
$ |
0.00 |
$ |
0.02 |
$ |
(0.01) |
|||||||||
Shares used for basic net income (loss) per share |
52,012 |
52,166 |
52,012 |
52,163 |
|||||||||||||
Shares used for diluted net income (loss) per share |
52,035 |
52,166 |
52,013 |
52,163 |
|||||||||||||
Balance Sheet Data |
||||||||
December 31, |
June 30, |
|||||||
Cash and cash equivalents |
$ |
5,400 |
$ |
5,564 |
||||
Total current assets |
28,493 |
27,495 |
||||||
Total assets |
64,134 |
63,261 |
||||||
Line of credit |
4,201 |
5,583 |
||||||
Current portion of long-term debt |
381 |
— |
||||||
Total current liabilities |
14,107 |
14,124 |
||||||
Stockholders' equity |
45,055 |
44,633 |
||||||
SOURCE Heska Corporation
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article